Fig. 1From: Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimenPatient flow. Abbreviations: BI = Boehringer Ingelheim; RT = randomized and treated; US = United StatesBack to article page